Loading stock data…
HUMA
$0.92+0.07 (+8.13%)
Market ClosedLast close May 4
Humacyte, Inc., together with its subsidiaries, engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Humacyte, Inc. in the Healthcare sector is trading at $0.92. The stock is currently near its 52-week low of $0.55, remaining 31.0% below its 200-day moving average. Technical signals show overbought RSI of 72 and bullish MACD crossover, explaining why HUMA maintains its current current market pressure. The Whystock Score of 0/100 signals elevated caution as indicators diverge.
Ecosystem Influences
Overbought levels (RSI 72) — risk of consolidation or pullback
Long-term trend bearish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$0.92
Potential Upside
5%
Whystock Fair Value$0.97
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus7 analysts
Buy
Mean target$5.07+448.4%
Range$1.00 – $25.00
Fundamentals
Humacyte, Inc., together with its subsidiaries, engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple th...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$156.50M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
2.10
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-1313.38%
Volume
Today's trading volume
4.35M
Recent News
A Look At Fresenius Medical Care (XTRA:FME) Valuation After The Symvess Distribution Agreement Revision
Fresenius Medical Care (XTRA:FME) is back in focus after Humacyte adjusted the ex U.S. distribution rights for Symvess, an acellular tissue engineered vessel, reshaping how the partners approach vascular access and regenerative medicine abroad. See our latest analysis for Fresenius Medical Care. The amended Symvess agreement lands at a time when Fresenius Medical Care’s €38.61 share price has seen a modest 1.34% 90 day share price return but a 12.44% decline in 1 year total shareholder...
Fresenius Medical Care’s Symvess Deal Shift And What It Means For Valuation
Fresenius Medical Care and Humacyte have amended their international rights agreement for Symvess, an acellular tissue engineered vessel. The revised deal realigns ex U.S. distribution rights, affecting how Symvess may be brought to markets outside the United States. The change reflects an adjustment in how the two companies plan to collaborate in vascular access and regenerative medicine globally. Fresenius Medical Care (XTRA:FME), trading at around €38.61, is adjusting its product...
Humacyte, Inc. (HUMA) Surpasses Market Returns: Some Facts Worth Knowing
In the closing of the recent trading day, Humacyte, Inc. (HUMA) stood at $0.84, denoting a +2.66% move from the preceding trading day.
Humacyte Highlights Dialysis Access Data; Women Show Strong ATEV Edge, V012 Results Due in June
Humacyte (NASDAQ:HUMA) outlined the unmet need in hemodialysis vascular access and highlighted data from its clinical program evaluating the company’s acellular tissue engineered vessel (ATEV) as an alternative to autologous arteriovenous fistulas (AVFs), with a particular focus on women, during a v
Humacyte, Inc. (HUMA) Stock Sinks As Market Gains: Here's Why
In the most recent trading session, Humacyte, Inc. (HUMA) closed at $0.7, indicating a -1.14% shift from the previous trading day.